Book a demo
Skip to content
AI agents for life sciences

Turn hidden patent data into smarter chemistry decisions.

Lead Compound Analyzer finds the compounds most likely to be the lead. SAR Extractor turns the structures and activity values into one reviewable table.

From disclosure to chemistry insight
Small molecule patent Structures Assays Experimental results Chemistry-aware recognition Lead Compound Analyzer Likely lead candidates SAR Extractor Connected activity data
Built for medicinal chemistry, cheminformatics and IP & patent intelligence teams.

Trusted by over 1,000 life science innovators.

Bristol Myers Squibb
Zymeworks
Sarepta Therapeutics
Sirius Therapeutics
Novartis
Vertex Pharmaceuticals
Johnson & Johnson
Boehringer Ingelheim
Sanofi
Novo Nordisk
Jazz Pharmaceuticals
BeOne Medicines
Focus your compound review

Lead Compound AnalyzerBeta

Reads the biological and experimental evidence disclosed in a patent and shortlists the likely leads, with the rationale for each.

  • Identify up to 10 likely lead compounds from a single patent.
  • Review potency, selectivity, in vivo findings and developability context where available.
  • Compare candidates grouped by evidence level, with supporting rationale and references.
Bring the findings to your team Word · Excel · SDF for recommended molecules
Lead Compound Analyzer
Input WO2022232536A1 One small molecule patent
Reading the evidence Potency · selectivity · in vivo · developability
Molecule recommendation Evidence level shown · not ranked
99 Chemical structure of compound 99 IKZF2 DC₅₀ 0.001 µM · 89% reduction at 30 µM, 6 hStructure P57 · Activity P98 Level 3
72 Chemical structure of compound 72 IKZF2 DC₅₀ 0.001 µM · 80% reduction at 30 µM, 6 hStructure P53 · Activity P98 Level 3
111 Chemical structure of compound 111 IKZF2 DC₅₀ 0.005 µM · hERG IC₅₀ >30 µMStructure P59 · Activity P98 Level 3
+ 7 more candidates in this report, each with rationale, references and predicted ADMET
Connect structures to activity

SAR ExtractorBeta

Uncover structure–activity relationships across patent disclosures without reconstructing every table by hand.

  • Process up to 10 small molecule patents per task, depending on your plan.
  • Connect structures with activity values, targets and experimental context.
  • Review confidence scores, run in-platform SAR analysis and export results for further investigation.
Take the data into your workflow CSV and Excel activity data · SDF structures and SMILES
SAR Extractor
WO2026132447A1Activity details · 311Compound summary · 274
Cpd 1 OOHONNHClNO MTHFD2 · IC₅₀50–500 nM HighHighTable 2 · P30
Cpd 2 NONHNOOOH MTHFD2 · IC₅₀500–5000 nM HighHighTable 2 · P30
Cpd 5 NH2ONHNONNNHN MTHFD2 · IC₅₀<50 nM HighHighTable 2 · P30

Confidence is scored separately for structure and activity. Three of 311 extracted activity rows shown.

01Extract structure & activity 02Review confidence & sources 03In-platform SAR analysis 04Export for further analysis

Near-real-time patent intelligence. Built for scientific review.

Patsnap’s OCSR, NER and NOR models connect chemical drawings, names and compound identities with patent evidence. Combined with layout analysis and ID mapping, they help turn new disclosures into usable chemistry data without waiting for manual curation.

OCSR Read chemical drawings

Optical Chemical Structure Recognition turns structure images into machine-readable chemistry.

Evaluated across 420+ randomly selected patent documents, 8.8K+ structures and 5.1K+ complete molecules.
97.06%OCSR precision
89.74%OCSR F1 score
NER Recognize chemical names

Named Entity Recognition identifies chemical entities in text and supports structure recovery from chemical names.

NOR Resolve compound identities

Entity normalization connects names and compound codes with known drug records where applicable.

Three ways teams use SAR Extractor and Lead Compound Analyzer.

01

Guide your next compound design

Compare structures and reported activity to inform hit-to-lead and lead optimization hypotheses.

02

Understand emerging competitor chemistry

Investigate newly disclosed compound series and likely leads alongside your program priorities.

03

Build reusable research datasets

Export structured records for expert curation, cheminformatics analysis and downstream modeling.

Works with

Use SAR Extractor and Lead Compound Analyzer alongside Patsnap Chemical and Synapse to explore related chemistry, patents and the wider drug landscape.

Frequently asked questions.

Which patents are best suited to these agents?

SAR Extractor focuses on organic small molecule patents with quantitative activity data and molecules below 900 Da. Files can be up to 50 MB each. Quality may decline for documents above 500 pages. Markush structures, biologic macromolecules, polymers and formulation-only patents are outside its scope.

Lead Compound Analyzer primarily supports small molecule patents and currently accepts a single patent number. Process, synthesis, formulation and method patents are not supported for lead analysis.

Can I analyze a newly published patent?

SAR Extractor supports direct PDF upload, so you can analyze a newly published document before it becomes available through patent-number search, within supported file and document limits.

Do the outputs still need scientific review?

Yes. Both agents are in beta. Extraction is not exhaustive, and performance varies with document length, layout and chemistry complexity. Use confidence scores, source references and expert review to validate critical findings before reuse.

How does Lead Compound Analyzer prioritize compounds?

It analyzes the biological and experimental evidence disclosed in a patent to identify the compounds most likely to be the lead. Up to 10 candidates are grouped by supporting evidence level for expert assessment, rather than assigned a numerical rank. Predicted ADMET properties are distinguished from experimental findings.

Can I export results to my existing tools?

SAR Extractor supports CSV and Excel for activity data and SDF for structures and SMILES. Lead Compound Analyzer supports Word, Excel and SDF exports for recommended molecules. Usage limits depend on your subscription.

Stop rebuilding the tables by hand.

SAR Extractor output table

WO2026132447A1 · Activity details (311) · Compound summary (274)

Compound CodeStructureStructure ConfidenceExperimental TargetEndpointValueUnitExperimental ObjectExperimental MethodActivity SourceActivity ConfidenceStructure Source
1 Cpd 1 Chemical structure of Cpd 1 High MTHFD2 IC50 50-500 nM MTHFD2 enzymatic assay Table 2 High
2 Cpd 1 Chemical structure of Cpd 1 High MTHFD1 IC50 20-250 µM MTHFD1 enzymatic assay Table 2 High
3 Cpd 2 Chemical structure of Cpd 2 High MTHFD2 IC50 500-5000 nM MTHFD2 enzymatic assay Table 2 High
4 Cpd 2 Chemical structure of Cpd 2 High MTHFD1 IC50 20-250 µM MTHFD1 enzymatic assay Table 2 High
5 Cpd 3 Chemical structure of Cpd 3 High MTHFD2 IC50 50-500 nM MTHFD2 enzymatic assay Table 2 High
6 Cpd 3 Chemical structure of Cpd 3 High MTHFD1 IC50 20-250 µM MTHFD1 enzymatic assay Table 2 High
9 Cpd 5 Chemical structure of Cpd 5 High MTHFD2 IC50 <50 nM MTHFD2 enzymatic assay Table 2 High

Seven of 311 extracted activity rows from a SAR Extractor share (October 2026). Scroll horizontally on smaller screens to inspect all columns.

Lead Compound Analyzer: sample report

Patent Molecule Recommendation Report

WO2022232536A1

Substituted 2-(2,6-dioxopiperidin-3-yl)-5-(1-piperidin-4-yl)isoindoline-1,3-dione derivatives and uses thereof. 10 candidate molecules recommended from one patent.

01 / Molecule recommendation

Compare candidates with their supporting evidence

Compound IDParsed structureStructure sourceRecommendation rationaleActivity referenceEvidence level
99Chemical structure of compound 99P57Recommended based on potent in vitro IKZF2 degradation, with a DC₅₀ of 0.001 µM and 89% IKZF2 reduction after 6 hours at 30 µM. No in vivo evidence is provided.P98Level 3
72Chemical structure of compound 72P53Recommended based on a 0.001 µM IKZF2 DC₅₀ and 80% IKZF2 reduction after 6 hours at 30 µM. The evidence is entirely in vitro.P98Level 3
111Chemical structure of compound 111P59Recommended based on a 0.005 µM IKZF2 DC₅₀, 83% IKZF2 reduction, and reported hERG IC₅₀ greater than 30 µM, providing both potency and an in vitro cardiac-ion-channel safety margin signal.P98Level 3

Seven further candidates (98, 128, 140, 35, 145, 7, 132) appear in the full report with the same fields.

02 / ADMET prediction

Model output alongside the measured evidence

Compound 99592.61 DaMW · LogP 1.67 · TPSA 154.8 Ų · hERG risk 0.50
Compound 72478.51 DaMW · LogP 0.98 · TPSA 129.1 Ų · hERG risk 0.28
Compound 111504.57 DaMW · LogP 2.18 · TPSA 119.9 Ų · hERG risk 0.46

Predicted values from the ADMET-AI tool, reported separately from the patent’s experimental findings.

Excerpt from a Lead Compound Analyzer shared report (October 2026), reformatted for this page. Values and references are reproduced from the report and require review against the original patent. Evidence level is shown; display order does not indicate rank.

Explore how this evidence could support your patent review.

Loading form…